Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease - Trial NCT06392425
Access comprehensive clinical trial information for NCT06392425 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Not yet recruiting. The study focuses on Chronic Kidney Diseases. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Assiut University
Timeline & Enrollment
N/A
Apr 26, 2024
Oct 31, 2027
Primary Outcome
To evaluate clinical utility of Serum ADAM 17 (A disintegrin and metalloprotease 17) and Caspase 3 measurement in chronic kidney disease patients
Summary
1. To evaluate clinical utility of Serum ADAM 17 (A disintegrin and metalloprotease 17) and
 Caspase 3 measurement in chronic kidney disease patients
 
 2. Study relationship of serum ADAM 17 and Caspase 3 to stages of chronic kidney disease
 
 3. Compare serum ADAM 17 and Caspase 3 levels in Diabetic Chronic kidney disease patients
 and Non Diabetic Chronic kidney disease patients
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06392425
Non-Device Trial